thought call
thought vertex result solid focu clearli
remain regulatori progress tripl combo cystic fibrosi cf inde
uncertainti long shift regard file new
week data quarter provid input ultim select either
regimen file nda view
fda like review file acceler manner given unmet need
het/min cf patient favor risk/benefit profil approv like
support risk adjust forecast vs con see vertex
pharmaceut tripl de-risk minor nda delay worst case
see robust uptak start us increment sale ou
lead indic littl sign demand flatten symdeko
y/i follow launch germani payer discuss ou market still
on-going think stori yet evolv cf given earli stage
pain fsg sickl cell program leverag tripl launch
robust help support upsid alreadi differenti growth profil
revenu compound-annual-growth-rate along emerg pipelin earli asset
reflect valuat support bullish stanc ow rate pt
pipelin updat outsid cf small molecul corrector phase
receiv fda track design clinic develop second asset
schedul first patient beta-thalassemia infus
first particip sickl cell diseas track infus
develop pre-clin inhibitor pain asset also plan
model adjust follow call adjust revenu
forecast respect non-gaap ep
estim respect
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight anticip near-term growth
kalydeco follow fda decis includ
residu function mutat bolster approv
symdeko earlier overal top-lin growth
larg depend upon develop success
tripl combin phase data posit
submiss plan
faster expect uptak orkambi ou
favor price persist complianc trend
continu expans kalydeco new cf
popul robust uptak symdeko global
rapid develop tripl combin
stagnat ou orkambi neg
discuss regul delay launch
reduc price development delay stumbl
tripl combo rapid develop emerg
compet product approach gene-
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
